Related Experiment Video
Updated: Jul 8, 2026
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Triple negative tumours: a critical review.
1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK. jorge.reis-filho@icr.ac.uk
Histopathology
|January 4, 2008
Summary
Triple-negative and basal-like breast cancers disproportionately affect young and African-American women. This review explores their aggressive behavior, links to BRCA1 mutations, and potential new therapeutic targets.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Breast cancer is a complex disease with diverse subtypes.
- Current treatments are tailored based on hormone receptor and HER2 status.
- Triple-negative breast cancer (TNBC) lacks these markers, limiting systemic therapy options.
Purpose of the Study:
- To review basal-like and triple-negative breast cancers.
- To compare their characteristics, clinical behavior, and chemotherapy response.
- To discuss novel therapeutic targets and BRCA1 pathway dysfunction.
Main Methods:
- Analysis of microarray expression profiling data.
- Review of clinical and histopathological parameters.
- Examination of biological characteristics and treatment responses.
Main Results:
- Basal-like breast cancers often exhibit a triple-negative phenotype.
- These aggressive cancers predominantly affect younger, African-American women.
- Significant overlap exists between sporadic TNBC, basal-like cancers, and BRCA1-associated breast cancers.
Conclusions:
- Basal-like and triple-negative breast cancers share aggressive features and are linked to BRCA1 dysfunction.
- Understanding these subtypes is crucial for developing targeted therapies.
- Further research into BRCA1 pathway mechanisms may reveal new treatment strategies.
